179 related articles for article (PubMed ID: 16213532)
1. Screening the receptorome for plant-based psychoactive compounds.
O'Connor KA; Roth BL
Life Sci; 2005 Dec; 78(5):506-11. PubMed ID: 16213532
[TBL] [Abstract][Full Text] [Related]
2. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery.
Roth BL; Lopez E; Beischel S; Westkaemper RB; Evans JM
Pharmacol Ther; 2004 May; 102(2):99-110. PubMed ID: 15163592
[TBL] [Abstract][Full Text] [Related]
3. Receptorome screening for CNS drug discovery.
Vortherms TA; Roth BL
IDrugs; 2005 Jun; 8(6):491-6. PubMed ID: 15906196
[TBL] [Abstract][Full Text] [Related]
4. Novel approaches to plant drug discovery based on high throughput pharmacological screening and genetic manipulation.
Littleton J; Rogers T; Falcone D
Life Sci; 2005 Dec; 78(5):467-75. PubMed ID: 16274700
[TBL] [Abstract][Full Text] [Related]
5. Biomedical analysis of New Psychoactive Substances (NPS) of natural origin.
Lo Faro AF; Di Trana A; La Maida N; Tagliabracci A; Giorgetti R; Busardò FP
J Pharm Biomed Anal; 2020 Feb; 179():112945. PubMed ID: 31704129
[TBL] [Abstract][Full Text] [Related]
6. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
7. Screening the receptorome: an efficient approach for drug discovery and target validation.
Strachan RT; Ferrara G; Roth BL
Drug Discov Today; 2006 Aug; 11(15-16):708-16. PubMed ID: 16846798
[TBL] [Abstract][Full Text] [Related]
8. [Neurological syndromes associated with the ingestion of plants and fungi with a toxic component (II). Hallucinogenic fungi and plants, mycotoxins and medicinal herbs].
Carod Artal FJ
Rev Neurol; 2003 May 16-31; 36(10):951-60. PubMed ID: 12766871
[TBL] [Abstract][Full Text] [Related]
9. The globalization of ayahuasca: harm reduction or benefit maximization?
Tupper KW
Int J Drug Policy; 2008 Aug; 19(4):297-303. PubMed ID: 18638702
[TBL] [Abstract][Full Text] [Related]
10. Screening the receptorome.
Kroeze WK; Roth BL
J Psychopharmacol; 2006 Jul; 20(4 Suppl):41-6. PubMed ID: 16785269
[TBL] [Abstract][Full Text] [Related]
11. Ligand screening system using fusion proteins of G protein-coupled receptors with G protein alpha subunits.
Suga H; Haga T
Neurochem Int; 2007; 51(2-4):140-64. PubMed ID: 17659814
[TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. Behavioral profile of constituents in ayahuasca, an Amazonian psychoactive plant mixture.
Freedland CS; Mansbach RS
Drug Alcohol Depend; 1999 May; 54(3):183-94. PubMed ID: 10372792
[TBL] [Abstract][Full Text] [Related]
14. Plants with neurobiological activity as potential targets for drug discovery.
Gomes NG; Campos MG; Orfão JM; Ribeiro CA
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1372-89. PubMed ID: 19666075
[TBL] [Abstract][Full Text] [Related]
15. Virtual screening strategies in drug discovery.
McInnes C
Curr Opin Chem Biol; 2007 Oct; 11(5):494-502. PubMed ID: 17936059
[TBL] [Abstract][Full Text] [Related]
16. Deorphanisation of G protein-coupled receptors: A tool to provide new insights in nervous system pathophysiology and new targets for psycho-active drugs.
Lecca D; Abbracchio MP
Neurochem Int; 2008 Feb; 52(3):339-51. PubMed ID: 17884255
[TBL] [Abstract][Full Text] [Related]
17. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges.
McKenna DJ
Pharmacol Ther; 2004 May; 102(2):111-29. PubMed ID: 15163593
[TBL] [Abstract][Full Text] [Related]
18. Rapid detection and validated quantification of psychoactive compounds in complex plant matrices by direct analysis in real time-high resolution mass spectrometry - Application to "Kava" psychoactive pepper products.
Chambers MI; Osborne AM; Musah RA
Rapid Commun Mass Spectrom; 2019 Dec; 33(24):1915-1925. PubMed ID: 31323704
[TBL] [Abstract][Full Text] [Related]
19. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
[TBL] [Abstract][Full Text] [Related]
20. High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Quinn MT
Mol Pharmacol; 2007 Apr; 71(4):1061-74. PubMed ID: 17229869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
